To include your compound in the COVID-19 Resource Center, submit it here.

Genentech begins Phase II of AC Immune's anti-Tau mAb for AD

AC Immune S.A. (NASDAQ:ACIU) said the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) started a Phase II trial of Anti Tau mAb (RO7105705) to

Read the full 244 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE